Section 7: Performance Measures for HPV NAT and LBC in the renewed NCSP

This section outlines the performance standards for HPV NAT and LBC which apply to collected samples taken by healthcare professionals and the requirements for calculating and reporting those measures to the RCPAQAP.

Performance Measures for HPV NAT and LBC apply to collected samples taken by health care professionals but not self-collected specimens. Most of the information required to calculate these measures will be provided to laboratories by the NCSR.

S7.1 The number and percentage of screening episodes reported as ‘unsatisfactory’ must be reported to the RCPAQAP.

Back to NPAAC Requirements

S7.2 Laboratories must provide the proportion of all technically satisfactory screening episodes reported in the categories low risk, intermediate risk and higher risk.

PM2a - the proportion of all technically satisfactory screening episodes reported in the categories low risk, intermediate risk and higher risk.
Laboratories must breakdown the risk categories for screening episodes to show underlying HPV NAT and LBC results.
Laboratories must provide a breakdown by birth cohorts of women born before and after 30th June 1980 to separate younger mostly vaccinated women from older unvaccinated women.

Back to NPAAC Requirements

S7.3 Laboratories must provide a breakdown of the HPV NAT and LBC results of all other episodes.

PM2b - a breakdown of the HPV NAT and LBC results of all other (non-screening, not self-collected) episodes.
Laboratories must provide a breakdown by birth cohorts of women born on or before and after 30th June 1980 to separate younger, mostly vaccinated women from older, unvaccinated women.

Back to NPAAC Requirements

S7.4 The proportion of LBC specimens reported as HSIL where cervical histopathology, taken within six months, confirms the abnormality as HSIL, AIS or cervical malignancy must be reported to the RCPAQAP.

PM3a and PM3b - The proportion of LBC specimens reported as HSIL/PHSIL (respectively) where cervical histopathology, taken within six months, confirms the abnormality as HSIL, AIS or cervical malignancy must be reported to the RCPAQAP.
Note that unlike Performance Measures 3a and 3b in the superseded Performance Measures for Australian Laboratories Reporting Cervical Cytology (3rd Edition 2015) which referred to all high grade intraepithelial lesions, including AIS, the Performance Measures now refer only to the positive predictive value of a cytology report of a high grade intraepithelial squamous lesion.

Back to NPAAC Requirements

S7.5 The proportion of LBC specimens reported as possible HSIL where cervical histopathology, taken within six months, confirms the abnormality as HSIL, AIS or cervical malignancy must be reported to the RCPAQAP.

PM3a and PM3b - The proportion of LBC specimens reported as HSIL/PHSIL (respectively) where cervical histopathology, taken within six months, confirms the abnormality as HSIL, AIS or cervical malignancy must be reported to the RCPAQAP.
Note that unlike Performance Measures 3a and 3b in the superseded Performance Measures for Australian Laboratories Reporting Cervical Cytology (3rd Edition 2015) which referred to all high grade intraepithelial lesions, including AIS, the Performance Measures now refer only to the positive predictive value of a cytology report of a high grade intraepithelial squamous lesion.

Back to NPAAC Requirements

S7.6 The proportion of women with histological diagnosis of HSIL or malignancy which were originally reported as low risk with a primary screening HPV NAT within the last 63 months must be reported.

Back to NPAAC Requirements

Copyright © 2019 RCPA. All rights reserved.

Website design and development by Big Blue Digital.

Top